Bullish on Inventiva (IVA) as a late-stage Phase 3 MASH drug developer with an oral candidate that could be the second approved MASH drug.
IVA — LONG The author is bullish on Inventiva, which is at the end of Phase 3 for its MASH drug lanifibranor. The drug is orally administered, unlike Madrigal's, and the author claims results are impressive, positioning it to become the second approved drug in the large MASH market. The author notes the company is under the radar, similar to Abivax previously, and states 'I'm in!'
The company is at the end of Phase 3 for its drug targeting MASH: lanifibranor.
This Reddit post, published January 13, 2026, features u/Beautiful-Cod-3414 discussing IVA. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Beautiful-Cod-3414 · Tickers: IVA